.jpg)
Join us for ANCO’s ASCO26 Highlights taking place at the InterContinental San Francisco on August 15, 2026!
Meeting Overview
ANCO’s ASCO26 Highlights will summarize the major research and treatment advancements presented at this year’s ASCO26 Annual Meeting.
Please note, this meeting is not in affiliation in any way with ASCO.
The program will focus on developmental therapeutics, breast, gastrointestinal, genitourinary, head and neck, gynecologic, lung, hematologic malignancies, sarcoma, as well as, melanoma, and end with a panel discussion.
The faculty will place these developments in context as to their immediate clinical utility.
Registration will open in late spring 2026.
Industry Registration is not open yet. Please read below to understand ANCO's industry registraiton waitlist process:
At ANCO, we strive to foster meaningful connections and facilitate valuable interactions among participants at our meetings. To ensure a fair distribution of attendance and provide an opportunity for various stakeholders to participate and engage with the cancer care community at large, industry registrations for our meetings are intentionally limited.Industry Registrations are limited to a maximum of three representatives per company, from companies who are not exhibiting at the meeting, with a maximum of 15 companies.
This policy is contingent upon meeting registrations and venue capacity. If we do have additional space, we will accept more representatives.
How does the ANCO Industry Registration waitlist approval process work?
- Six weeks prior to the meeting starting, ANCO will begin approving industry registrations from the waitlist, priority will be given to industry representatives who are not exhibiting.
- Two weeks prior to ANCO meetings, ANCO will review the remaining waitlisted industry registrations. If additional space is available, ANCO may approve up to three additional industry registrations per company on the waitlist.
